Mattia Rediti

Global alliances in translational cancer research Translating basic cancer biology into effective clinical therapies remains a major challenge due to differences in research models, communication gaps, and limited funding. This commentary underscores the transformative potential of international collaborations, which integrate diverse resources, multidisciplinary talent, and innovative trial designs to bridge the gap between laboratory discoveries and clinical applications. By fostering global alliances, sharing knowledge, and harmonizing regulatory and funding frameworks, we can accelerate breakthroughs in cancer treatment, improving patient outcomes worldwide.

Global alliances in translational cancer research

Leveraging real-world data to advance biomarker discovery and precision oncology Precision oncology is predicated on the availability of robust biomarkers deployed at scale at the point of care. Although simple in conception, precision oncology often fails in practice because of the limitations of current diagnostic platforms, the emergence of drug resistance, an incomplete understanding of cancer pathogenesis, and the host immune response. Here, we discuss using real-world data, including exceptional responder analyses, to identify biomarkers of therapy response and strategies for overcoming barriers to the broader adoption of precision-oncology paradigms.

Leveraging real-world data to advance biomarker discovery and precision oncology

Turn cold tumors hot by reprogramming the tumor microenvironment - Nature Biotechnology The identification of novel targets together with technological advances is transforming our ability to effectively modulate the tumor microenvironment.

Turn cold tumors hot by reprogramming the tumor microenvironment - @mdanderson.bsky.social go.nature.com/42Bo9lT

#SABCS24 #bcsm #OncSky

Dr. J O’Shaughnessy presents prespecified exploratory biomarker analysis of KN522 trial of pembro in #breastcancer

See pics ⬇️ for conclusions & link or QR code for full results:
bit.ly/3CejYmo

@oncoalert.bsky.social

Method of the Year 2024: spatial proteomics - Nature Methods Approaches for profiling the spatial proteome in tissues are the basis of atlas-scale projects that are delivering on their promise for understanding biological complexity in health and disease.

I could not be more thrilled to announce the Nature Methods @naturemethods.bsky.social Method of the Year is Spatial Proteomics! Please see our editorial as a roadmap to the fantastic content in this special issue! www.nature.com/articles/s41...

Genetic immune escape in cancer: timing and implications for treatment Genetic immune escape (GIE) alterations pose a significant challenge in cancer by enabling tumors to evade immune detection. These alterations, which …

Excited to share our perspective on genetic immune escape alterations and their impact on tumor evolution, metastasis, immunotherapy, and interactions with tumor-extrinsic factors. It was a pleasure collaborating with Diego on this -hope you enjoy the read!☺️

www.sciencedirect.com/science/arti...

A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy - Nature Biotechnology The neoantigen discovery pipeline NeoDisc incorporates mass spectrometry immunopeptidomics data.

A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy

www.nature.com/articles/s41...

Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial - Nature Communications The clinical implications of molecular heterogeneity in HER2-positive breast cancer remain to be explored. Here, the authors investigate the transcriptomic landscape of HER2-positive breast cancer pat...

Our work on HER2+ breast cancer heterogeneity (from my PhD with Christos Sotiriou at the Institut Jules Bordet) is out @naturecomms.bsky.social

➡️5 molecular subtypes 🧬 identified in the ALTTO trial with external validations

Grateful to Christos and all co-Authors

www.nature.com/articles/s41...

Spatial transcriptomics reveals substantial heterogeneity in triple-negative breast cancer with potential clinical implications - Nature Communications Triple-negative breast cancer (TNBC) is a heterogenous disease with several molecular subtypes previously described. Here the authors perform a spatial transcriptomics analysis on a series of 92 patie...

Out in @NatureComms further evidence that TNBC is an heterogeneous disease

Spatial Transcriptomics is emerging as a powerful tool to assess the spatial architecture of TNBC, with implications on clinical outcomes and response to treatment

@oncoalert.bsky.social

www.nature.com/articles/s41...

Recommendations for Bioinformatics in Clinical Practice https://www.biorxiv.org/content/10.1101/2024.11.23.624993v1 🧬🖥️🧪

Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer Denkert et al. evaluate the longitudinal changes in tumor tissue of triple-negative breast cancer in a clinical trial cohort treated with neoadjuvant immunotherapy plus chemotherapy. The role of diffe...

Correlative analysis of GeparNuevo #TNBC neoadj clinical trial by Denkert et al:
➡️Expression analyses of tumor biopsies at 3 time points
➡️Confirm role of immune & prolif signatures
➡️Stromal signature assoc w immunotherapy resistance

@oncoalert.bsky.social #BCSM

www.cell.com/cell-reports...

In today's Nature: A ‘Wikipedia for cells’
www.nature.com/articles/d41...
www.nature.com/immersive/d4...

MultiOmicsIntegrator-MOI: A nextflow pipeline for integrated omics analyses https://academic.oup.com/bioinformaticsadvances/advance-article/doi/10.1093/bioadv/vbae175/7900314

The Human Tumor Atlas Network (HTAN): exploring tumor evolution in time and space Studying the evolution of cancer malignancy in space and time provides clues that are crucial for understanding how tumors develop, how they evade the immune ...

The Human Tumor Atlas Network - 3D atlases that integrate cellular, molecular & histological features of diverse tumors across their evolution

In this ongoing collection, @natureportfolio.bsky.social showcases tools, datasets & insights from the network

www.nature.com/collections/...